In squamous cell carcinoma of the vulva, overexpression of p53 is a late event and neither p53 nor mdm2 expression is a useful marker to predict lymph node metastases

British Journal of Cancer

Volumn 80, Issue 1-2, 1999, Pages 38-43

  Emanuels, A G ^a,b   Koudstaal, J ^a   Burger, M P M ^a   Hollema, H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

mdm2; Metastasis; p53; Vulvar carcinoma

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CARCINOGENESIS; CLINICAL GENETICS; EPITHELIUM CELL; EPITHELIUM TUMOR; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MATHEMATICAL AND STATISTICAL PROCEDURES; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; VULVA CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; VULVAR NEOPLASMS;

EID: 0032918469     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690318     Document Type: Article

References (34)

1. Barak Y, Juven T, Haffner R and Oren M (1993) mdm2 expression is induced by wild type p53 activity. EMBO J 12: 461-468
2. Bosari S and Viale G (1995) The clinical significance of p53 aberrations in human tumors. Virchows Arch 427: 229-241
3. Bosari S, Viale G, Roncalli M, Graziani D, Borsani G, Lee AK and Coggi G (1995) p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am J Pathol 147: 790-798
4. Charpin C, Devictor B, Andrac L, Amabile J, Bergeret D, Allasia C and Piana L and LaVaut MN (1995) p53 quantitative immunocytochemical analysis in breast carcinomas. Hum Pathol 26: 159-166
5. Chu J, Tamimi H, Ek M and Figge D (1982) Stage I vulvar cancer: criteria for microinvasion. Obstet Gynecol 59: 716-719
6. Coulter LK, Wolber R and Tron VA (1995) Site-specific comparison of p53 immunostaining in squamous cell carcinomas. Hum Pathol 26: 531-533
7. Dazard J, Augias D, Neel H, Mils V, Marechal V, Basset-Seguin N and Piette J (1997) Mdm2 protein is expressed in different layers of normal human skin. Oncogene 14: 1123-1128
8. Emanuels A, Hollema H, Suurmeyer A and Koudstaal J (1994) A modified method for antigen retrieval MIB-1 staining of vulvar carcinoma. Eur J Morphol 32: 335-337
9. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA and Cote RJ (1994) Accumulation of nuclear p53 and tumor progression in bladder cancer [see comments]. N Engl J Med 331: 1259-1264
10. Esrig D, Spruck CH, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen SC, Skinner DG, Jones PA and Cote RJ (1993) p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143: 1389-1397
11. Florenes VA, Oyjord T, Holm R, Skrede M, Borresen AL, Nesland JM and Fodstad O (1994) TP53 allele loss, mutations and expression in malignant melanoma. Br J Cancer 69: 253-259
12. Hartwell LH and Kastan MB (1994) Cell cycle control and cancer. Science 266: 1821-1828
13. Kagie M, Kenter G, Tollenaar R, Hermans J, Baptist Trimbos J and Fleuren G (1997) p53 protein overexpression is common and independent of human papillomavirus infection in squamous cell carcinoma of the vulva. Cancer 80: 1228-1233
14. Kennedy SM, Macgeogh C, Jaffe R and Spurr NK (1994) Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with gene mutations [see comments]. Hum Pathol 25: 438-442
15. Kessis TD, Slebos RJ, Han SM, Shah K, Bosch XF, Munoz N, Hedrick L and Cho KR (1993) p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix. Am J Pathol 143: 1398-1405
16. King LA, Okagaki T, Gallup DC, Twiggs LB, Messing MJ and Carson LF (1996) Mitotic count, nuclear atypia, and immunohistochemical determination of Ki-67, c-myc, p21-ras, c-erbB2, and p53 expression in granulosa cell tumors of the ovary: mitotic count and Ki-67 are indicators of poor prognosis. Gynecol Oncol 61: 227-232
17. Kohlberger P, Kainz C, Breitenecker G, Gitsch G, Sliutz G, Kolbl H, Tschachler E and Reinthaller A Prognostic value of immunohistochemically detected p53 expression in vulvar carcinoma. Cancer 76: 1786-1789
18. Lane DP (1992) p53, guardian of the genome. Nature 358: 15-16
19. Lassam NJ, From L and Kahn HJ (1993) Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 53: 2235-2238
20. Marchetti A, Buttitta F, Pellegrini S, Merlo G, Chella A, Angeletti CA and Bevilacqua G (1995) mdm2 gene amplification and overexpression in non-small cell lung carcinomas with accumulation of the p53 protein in the absence of p53 gene mutations. Diagn Mol Pathol 4: 93-97
21. McCann AH, Kirley A, Carney DN, Corbally N, Magee HM, Keating G and Dervan PA (1995) Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br J Cancer 71: 981-985
22. Milde-Langosch K, Albrecht K, Joram S, Schlechte H, Giessing M and Loning T (1995) Presence and persistence of HPV infection and p53 mutation in cancer of the cervix and the vulva. Int J Cancer 63: 639-645
23. Momand J, Zambetti GP, Olson DC, George D and Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245
24. Ofner D, Maier H, Riedmann B, Holzberger P, Nogler M, Totsch M, Bankfalvi A, Winde G, Bocker W and Schmid K (1995) Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in colorectal carcinoma: prognostic significance. J Clin Pathol Mol Pathol 48: 12-16
25. Oliner JD, Kinzler KW, Meltzer PS, George DL and Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas [see comments]. Nature 358: 80-83
26. Prokocimer M and Rotter V (1994) Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages. Blood 84: 2391-2411
27. Przygodzki RM, Finkelstein SD, Langer JC, Swalsky PA, Fishback N, Bakker A, Guinee DG, Koss M and Travis WD (1996) Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome. Am J Pathol 148: 1531-1541
28. Quesnel B, Preudhomme C, Fournier J, Fenaux P and Peyrat JP, (1994) MDM2 gene amplification in human breast cancer. Eur J Cancer 30A: 982-984
29. Shurbaji MS, Kalbfleisch JH and Thurmond TS (1995) Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 26: 106-109
30. Sun XF, Carstensen JM, Zhang H, Stal O, Wingren S, Hatschek T and Nordenskjold B (1992) Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 340: 1369-1373
31. Vogt T, Zipperer KH, Vogt A, Holzel D, Landthaler M and Stolz W (1997) p53-protein and Ki-67 antigen expression are both reliable biomarkers of prognosis in thick stage 1 nodular melanomas of the skin. Histopathology 30: 57-63
32. Wu X, Bayle J, Olson D and Levine A (1993) The p53-mdm2 autoregulatory feedback loop. Genes Dev 7: 1126-1132
33. Xerri L, Bouabdallah R, Camerlo J and Hassoun J (1994) Expression of the p53 gene in Hodgkin's disease: dissociation between immunohistochemistry and clinicopathological data. Hum Pathol 25: 449-454
34. Younes M, Lebovitz RM, Bommer KE, Cagle PT, Morton D, Khan S and Laucirica R (1995) p53 accumulation in benign breast biopsy specimens. Hum Pathol 26: 155-158